Topics:

ubmslateCL-logo-ubm

CL Mobile Menu

RA response criteria help decisions about continuing TNF inhibitors

RA response criteria help decisions about continuing TNF inhibitors

The key predictors for continuation of anti–tumor necrosis factor α treatment in patients with rheumatoid arthritis (RA) are response and achievement of a state of low disease activity. Responses seen after 6 weeks and, significantly, after 3 months help decision making.

Glfe and colleagues monitored a group of 1789 Swedes with RA who had started their first course of treatment. Response to therapy was assessed at 6 weeks and at 3 months according to American College of Rheumatology (ACR), European League Against Rheumatism (EULAR), and Simple Disease Activity Index (SDAI)/Clinical Disease Activity Index (CDAI) criteria.

The percentages of patients who responded at the lowest level (ACR20, EULAR overall and modified, and SDAI/CDAI overall criteria) were 55% to 75% at 6 weeks and 61% to 80% at 3 months. The percentages of patients who responded at a higher level (ACR50, EULAR good, SDAI/CDAI major) were 29% to 44% at 6 weeks and 34% to 57% at 3 months. Patients most likely to continue treatment were those who achieved ACR20 and ACR50 responses at 6 weeks and all levels of ACR response at 3 months.

The authors noted that little change in overall treatment response takes place between the time points.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.